Clinical trials
Neuroendocrine Tumors clinical trials
Below are recruiting neuroendocrine tumors clinical trials, each written for real people, not researchers. We’re tracking 173 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04104529Recruiting
Registry study for adults getting metabolic radiotherapy
This trial collects health and lab information from adults treated with metabolic radiotherapy in the nuclear medicine department. It may help doctors better understand how these treatments work for thyroid cancer, neuroendocrine tumors, or prostate cancer.
Bordeaux, AquitaineAges 18 years+ - NCT06121622Recruiting
Personalized 3D models for pancreatic neuroendocrine tumors
This study is testing a new way to make 3D models in the lab that look like your specific tumor. The goal is to better understand pancreatic neuroendocrine tumors and find personalized treatments.
Milan, MIAges 18 years+ - NCT06402695Recruiting
Observational study on digestive and lung NETs
This study follows people with a type of tumor called a neuroendocrine tumor (NET) that started in the digestive system or lungs, to learn more about how the disease progresses and how it responds to treatment.
RomeAges 18 years+ - NCT05794048Recruiting
Study of blood and tumor features in liver and pancreatic cancers
This trial looks at a patient’s “metabolic profile” (how the body’s chemicals are used) in people with certain liver and pancreatic tumors. It may help doctors better understand these cancers and improve how they are evaluated for treatment.
ClichyAges 18 years+ - NCT05701241RecruitingPhase 4
Test continuing somatostatin shots after tumor progression in GEP NET
This trial studies whether it’s helpful to keep taking somatostatin “analog” injections even after your neuroendocrine tumor has started growing despite the usual dose. It also looks at how the next treatment choice (targeted pills or PRRT) fits in for people with non-functional, well-differentiated GEP NET.
Brasschaat, AntwerpAges 18 years+ - NCT07728292Recruiting
Underwater removal of small gastric neuroendocrine tumors
This trial tests a special underwater technique to remove small type I gastric neuroendocrine tumors (5-9 mm) during an endoscopy. The goal is to see if it is safe and effective, which could offer a less invasive treatment option.
Hyderabad, TelanganaAges 18–65 - NCT04954820RecruitingPhase 2
Second round Lutathera for intestinal NET after regrowth
This Phase 2 study looks at whether giving Lutathera again (a second round) can control an intestinal neuroendocrine tumor (NET) that came back or progressed after the first treatment. It mainly targets adults whose scan shows tumors still take up the right “target” signal and who previously benefited for at least 12 months.
AngersAges 18 years+ - NCT05037461Recruiting
MR-guided radiation for pancreas tumors in MEN1 patients
This study tests a precise, MRI-guided radiation plan for certain small pancreas neuroendocrine tumors in people with MEN1. It may help control tumor growth when surgery is needed or when remaining small tumor spots are left after prior surgery.
UtrechtAges 18 years+ - NCT05554003RecruitingPhase 2
Low-grade neuroendocrine tumors: metronomic temozolomide for frail patients
This Phase 2 study tests a gentler, steady schedule of temozolomide in people with advanced low-grade neuroendocrine neoplasms who are “unfit” for stronger treatments. The goal is to shrink or control the cancer while being safer for people with weaker health or organ function.
MilanAges 18 years+ - NCT06937112Recruiting
A new scan for early detection of certain cancers
This trial tests a new imaging agent (18F-FAPI) to see if it can help find tumors early in people with lung, thyroid, pancreatic, melanoma, or neuroendocrine cancers.
Nanjing, JiangsuAges 18–75 - NCT07273409Recruiting
Surgery for advanced pancreatic neuroendocrine tumors
This trial tests whether surgically removing as much of the tumor as possible (debulking) is better than not doing surgery for people with advanced pancreatic neuroendocrine tumors. It aims to see if this approach can improve outcomes.
GothenburgAges 18 years+ - NCT07458906Recruiting
DLL3-targeted PET/CT scan for neuroendocrine cancer
This trial uses a special PET/CT scan that targets a substance called DLL3, found on some cancer cells, to see if doctors can better detect or monitor neuroendocrine carcinoma. It may help you and your doctor get clearer information about your cancer.
Xiamen, FujianAges 18–80 - NCT07369505RecruitingPhase 1
A study of Sapu003 for advanced tumors sensitive to mTOR
This trial tests a new drug, Sapu003, in people with certain advanced cancers that may respond to mTOR-targeted therapy. It is looking at two groups: postmenopausal women with a type of breast cancer (HR+/HER2-), and adults with kidney, liver, neuroendocrine, or TSC-related tumors. The goal is to see if Sapu003 is safe and effective.
AdelaideAges 18 years+ - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
Huntsville, AlabamaAges 18 years+ - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Greenwood Village, ColoradoAges 19–110 - NCT04949282Recruiting
Lutetium-177 treatment for advanced somatostatin-positive tumors
This study looks at outcomes for adults with tumors that are advanced (can’t be fully removed or has spread) and are getting worse, where tests show somatostatin receptors. It aims to understand how treatment with lutetium-177 helps people in this situation.
Santiago de Compostela, A CoruñaAges 18–100 - NCT06430021Recruiting
Blood test for neuroendocrine tumors in MEN1
This study is testing a new blood test to see if it can help diagnose neuroendocrine tumors in people with MEN1, a genetic condition that increases the risk of these tumors. The test looks for a protein called hPG80 (progastrin) and may help doctors find tumors earlier.
DijonAges 18–60 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT06256705Recruiting
Study of targeted radiation for neuroendocrine tumors
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
ClichyAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT04907643Recruiting
Virtual reality program to reduce stomach-cancer pain
This trial tests whether virtual reality (VR) can improve pain and other day-to-day symptoms in people with certain gastrointestinal cancers. You’d use VR for pain relief while researchers measure how you’re feeling.
Los Angeles, CaliforniaAges 18–99
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine tumors?
- Yes. Clin2 currently lists 173 recruiting neuroendocrine tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.